Home Nanotechnology TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric most cancers | Journal of Nanobiotechnology

TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric most cancers | Journal of Nanobiotechnology

0
TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric most cancers | Journal of Nanobiotechnology

[ad_1]

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. International most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J Clin. 2021;71:209–49.

    Article 
    PubMed 

    Google Scholar
     

  • Rugge M, Meggio A, Pravadelli C, Barbareschi M, Fassan M, Gentilini M, Zorzi M, Pretis G, Graham DY, Genta RM. Gastritis staging within the endoscopic follow-up for the secondary prevention of gastric most cancers: a 5-year potential examine of 1755 sufferers. Intestine. 2019;68:11–7.

    Article 
    PubMed 

    Google Scholar
     

  • Shah MA, Bodoky G, Starodub A, Cunningham D, Yip D, Wainberg ZA, Bendell J, Thai D, He J, Bhargava P, et al. Part III examine to judge efficacy and security of andecaliximab with mFOLFOX6 as first-line remedy in sufferers with superior gastric or GEJ adenocarcinoma (GAMMA-1). J Clin Oncol. 2021;39:990–1000.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Constantinidou A, Alifieris C, Trafalis DT. Concentrating on programmed cell demise – 1 (PD-1) and Ligand (PD-L1): a brand new period in most cancers energetic immunotherapy. Pharmacol Ther. 2019;194:84–106.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Andrea AE, Chiron A, Mallah S, Bessoles S, Sarrabayrouse G, Hacein-Bey-Abina S. Advances in CAR-T cell genetic engineering methods to beat hurdles in stable tumors remedy. Entrance Immunol. 2022;13:830292.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca Ok, Adam V. Hypoxia-inducible components: grasp regulators of hypoxic Tumor immune Escape. J Hematol Oncol. 2022;15:77.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wei X, Chen Y, Jiang X, Peng M, Liu Y, Mo Y, Ren D, Hua Y, Yu B, Zhou Y, et al. Mechanisms of vasculogenic mimicry in hypoxic Tumor microenvironments. Mol Most cancers. 2021;20:7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Haanen J. Changing chilly into scorching tumors by combining immunotherapies. Cell. 2017;170:1055–56.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • van Duijn A, Willemsen KJ, van Uden NOP, Hoyng L, Erades S, Koster J, Luiten RM, Bakker WJ. A secondary function for hypoxia and HIF1 within the regulation of (IFNγ-induced) PD-L1 expression in Melanoma. Most cancers Immunol Immunother. 2022;71:529–40.

    Article 
    PubMed 

    Google Scholar
     

  • Bailey CM, Liu Y, Liu M, Du X, Devenport M, Zheng P, Liu Y, Wang Y. Concentrating on HIF-1α abrogates PD-L1-mediated immune evasion in Tumor microenvironment however promotes tolerance in regular tissues. J Clin Make investments. 2022;132.

  • Smith V, Mukherjee D, Lunj S, Choudhury A, Hoskin P, West C, Illidge T. The impact of hypoxia on PD-L1 expression in Bladder most cancers. BMC Most cancers. 2021;21:1271.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ding XC, Wang LL, Zhang XD, Xu JL, Li PF, Liang H, Zhang XB, Xie L, Zhou ZH, Yang J, et al. The connection between expression of PD-L1 and HIF-1α in glioma cells underneath hypoxia. J Hematol Oncol. 2021;14:92.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Solar Y, Tan J, Miao Y, Zhang Q. The function of PD-L1 within the immune dysfunction that mediates hypoxia-induced a number of organ damage. Cell Commun Sign. 2021;19:76.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hugo W, Zaretsky JM, Solar L, Track C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, et al. Genomic and transcriptomic options of response to Anti-PD-1 remedy in metastatic Melanoma. Cell. 2016;165:35–44.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zandberg DP, Menk AV, Velez M, Normolle D, DePeaux Ok, Liu A, Ferris RL, Delgoffe GM. Tumor hypoxia is related to resistance to PD-1 blockade in squamous cell carcinoma of the top and neck. J Immunother Most cancers. 2021;9(5):e002088.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chida Ok, Kawazoe A, Suzuki T, Kawazu M, Ueno T, Takenouchi Ok, Nakamura Y, Kuboki Y, Kotani D, Kojima T, et al. Transcriptomic profiling of MSI-H/dMMR gastrointestinal tumors to determine determinants of responsiveness to anti-PD-1 remedy. Clin Most cancers Res. 2022;28:2110–17.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Teng W, Zhao L, Yang S, Zhang C, Liu M, Luo J, Jin J, Zhang M, Bao C, Li D, et al. The hepatic-targeted, resveratrol loaded nanoparticles for reduction of excessive fats diet-induced nonalcoholic fatty Liver Illness. J Management Launch. 2019;307:139–49.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wang Y, Yu J, Luo Z, Shi Q, Liu G, Wu F, Wang Z, Huang Y, Zhou D. Engineering endogenous tumor-associated macrophage-targeted biomimetic nano-RBC to reprogram Tumor immunosuppressive microenvironment for enhanced chemo-immunotherapy. Adv Mater. 2021;33:e2103497.

    Article 
    PubMed 

    Google Scholar
     

  • Zhang YX, Zhao YY, Shen J, Solar X, Liu Y, Liu H, Wang Y, Wang J. Nanoenabled modulation of acidic Tumor microenvironment reverses anergy of infiltrating T cells and potentiates anti-PD-1 remedy. Nano Lett. 2019;19:2774–83.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Chen Q, Chen J, Yang Z, Xu J, Xu L, Liang C, Han X, Liu Z. Nanoparticle-enhanced radiotherapy to set off strong most cancers immunotherapy. Adv Mater. 2019;31:e1802228.

    Article 
    PubMed 

    Google Scholar
     

  • Track M, Liu T, Shi C, Zhang X, Chen X. Bioconjugated manganese dioxide nanoparticles improve chemotherapy response by priming tumor-associated macrophages towards M1-like phenotype and attenuating Tumor hypoxia. ACS Nano. 2016;10:633–47.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, Kelly CJ, Pirovano G, Buffa FM, Hammond EM, et al. The anti-malarial atovaquone will increase radiosensitivity by assuaging tumour hypoxia. Nat Commun. 2016;7:12308.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Liapis V, Labrinidis A, Zinonos I, Hay S, Ponomarev V, Panagopoulos V, DeNichilo M, Ingman W, Atkins GJ, Findlay DM, et al. Hypoxia-activated pro-drug TH-302 reveals potent Tumor suppressive exercise and cooperates with chemotherapy in opposition to osteosarcoma. Most cancers Lett. 2015;357:160–69.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Portwood S, Lal D, Hsu YC, Vargas R, Johnson MK, Wetzler M, Hart CP, Wang ES. Exercise of the hypoxia-activated prodrug, TH-302, in preclinical human acute Myeloid Leukemia fashions. Clin Most cancers Res. 2013;19:6506–19.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Jayaprakash P, Ai M, Liu A, Budhani P, Bartkowiak T, Sheng J, Ager C, Nicholas C, Jaiswal AR, Solar Y, et al. Focused hypoxia discount restores T cell infiltration and sensitizes Prostate most cancers to immunotherapy. J Clin Make investments. 2018;128:5137–49.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ma P, Chen J, Qu H, Li Y, Li X, Tang X, Track Z, Xin H, Zhang J, Nai J, et al. Hypoxic focusing on and activating TH-302 loaded transcatheter arterial embolization microsphere. Drug Deliv. 2020;27:1412–24.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lee AT, Pollack SM, Huang P, Jones RL. Part III smooth tissue sarcoma trials: success or failure? Curr Deal with Choices Oncol. 2017;18:19.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cutsem EV, Lenz H-J, Furuse J, Tabernero J, Heinemann V, Ioka T, Bazin I, Ueno M, Csõszi T, Wasan H, et al. MAESTRO: a randomized, double-blind part III examine of evofosfamide (Evo) together with gemcitabine (gem) in beforehand untreated sufferers (pts) with metastatic or regionally superior unresectable pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2016;34:4007–07.

    Article 

    Google Scholar
     

  • Hu S, Zhang Y. Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo analysis. Int J Nanomedicine. 2010;5:1039–48.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Nasrullah MZ. Caffeic acid phenethyl ester loaded PEG-PLGA nanoparticles improve wound therapeutic in diabetic rats. Antioxid (Basel). 2022;12.

  • Rafiei P, Haddadi A. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous software: pharmacokinetics and biodistribution profile. Int J Nanomedicine. 2017;12:935–47.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Mai Z, Zhong J, Zhang J, Chen G, Tang Y, Ma W, Li G, Feng Z, Li F, Liang XJ et al. Service-free immunotherapeutic nano-booster with twin synergistic results primarily based on glutaminase inhibition mixed with photodynamic remedy. ACS Nano. 2023.

  • Rennick JJ, Johnston APR, Parton RG. Key rules and strategies for learning the endocytosis of organic and nanoparticle therapeutics. Nat Nanotechnol. 2021;16:266–76.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hua L, Wang Z, Zhao L, Mao H, Wang G, Zhang Ok, Liu X, Wu D, Zheng Y, Lu J, et al. Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy. Theranostics. 2018;8:5088–105.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Galluzzo M, Pennacchietti S, Rosano S, Comoglio PM, Michieli P. Prevention of hypoxia by myoglobin expression in human Tumor cells promotes differentiation and inhibits Metastasis. J Clin Make investments. 2009;119:865–75.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Huff WX, Kwon JH, Henriquez M, Fetcko Ok, Dey M. The evolving function of CD8(+)CD28(-) immunosenescent T cells in most cancers immunology. Int J Mol Sci. 2019;20.

  • Huang W, Jiang Y, Xiong W, Solar Z, Chen C, Yuan Q, Zhou Ok, Han Z, Feng H, Chen H, et al. Noninvasive imaging of the Tumor immune microenvironment correlates with response to immunotherapy in gastric most cancers. Nat Commun. 2022;13:5095.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Huang Y, Tian Y, Zhao Y, Xue C, Zhan J, Liu L, He X, Zhang L. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo. Most cancers Commun (Lond). 2018;38:15.

    PubMed 

    Google Scholar
     

  • Li Y, Zhao L, Li XF. The hypoxia-activated prodrug TH-302: exploiting hypoxia in most cancers remedy. Entrance Pharmacol. 2021;12:636892.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Van Cutsem E, Lenz H-J, Furuse J, Tabernero J, Heinemann V, Ioka T, Bazin I, Ueno M, Csõszi T, Wasan H, et al. A randomized, double-blind part III examine of evofosfamide (Evo) together with gemcitabine (gem) in beforehand untreated sufferers (pts) with metastatic or regionally superior unresectable pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2016;MAESTRO:34:4007–07.

    Article 

    Google Scholar
     

  • Gaonkar RH, Ganguly S, Dewanjee S, Sinha S, Gupta A, Ganguly S, Chattopadhyay D, Chatterjee Debnath M. Garcinol loaded vitamin E TPGS emulsified PLGA nanoparticles: preparation, physicochemical characterization, in vitro and in vivo research. Sci Rep. 2017;7:530.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a technique for bettering nanoparticle-based drug and gene supply. Adv Drug Deliv Rev. 2016;99:28–51.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Liu P, Yu H, Solar Y, Zhu M, Duan Y. A mPEG-PLGA-b-PLL copolymer provider for adriamycin and siRNA supply. Biomaterials. 2012;33:4403–12.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wang H, Zhao Y, Wu Y, Hu YL, Nan Ok, Nie G, Chen H. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011;32:8281–90.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Acharya S, Sahoo SK. PLGA nanoparticles containing varied anticancer brokers and tumour supply by EPR impact. Adv Drug Deliv Rev. 2011;63:170–83.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kang H, Rho S, Stiles WR, Hu S, Baek Y, Hwang DW, Kashiwagi S, Kim MS, Choi HS. Measurement-dependent EPR impact of polymeric nanoparticles on Tumor focusing on. Adv Healthc Mater. 2020;9:e1901223.

    Article 
    PubMed 

    Google Scholar
     

  • Pastore C. Measurement-dependent nano-bio interactions. Nat Nanotechnol. 2021;16:1052.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zhang Y, Zhu J, Zhang Z, He D, Zhu J, Chen Y, Zhang Y. Reworking of Tumor microenvironment for enhanced Tumor chemodynamic/photothermal/chemo-therapy. J Nanobiotechnol. 2022;20:388.

    Article 

    Google Scholar
     

  • Chen C, Guo Q, Fu H, Yu J, Wang L, Solar Y, Zhang J, Duan Y. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative Breast most cancers development and Metastasis. Biomaterials. 2021;275:120988.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zhong Y, Meng F, Deng C, Zhong Z. Ligand-directed energetic tumor-targeting polymeric nanoparticles for most cancers chemotherapy. Biomacromolecules. 2014;15:1955–69.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zhang Z, Qian H, Huang J, Sha H, Zhang H, Yu L, Liu B, Hua D, Qian X. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to boost focusing on and antitumor capability in Colorectal most cancers remedy. Int J Nanomedicine. 2018;13:4961–75.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • [ad_2]

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here